162 related articles for article (PubMed ID: 26967453)
1. Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma.
Dotan E; Alpaugh RK; Ruth K; Negin BP; Denlinger CS; Hall MJ; Astsaturov I; McAleer C; Fittipaldi P; Thrash-Bingham C; Meropol NJ; Cohen SJ
Pancreas; 2016 Sep; 45(8):1131-5. PubMed ID: 26967453
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
[TBL] [Abstract][Full Text] [Related]
4. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
[TBL] [Abstract][Full Text] [Related]
5. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
[TBL] [Abstract][Full Text] [Related]
6. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker.
Khoja L; Backen A; Sloane R; Menasce L; Ryder D; Krebs M; Board R; Clack G; Hughes A; Blackhall F; Valle JW; Dive C
Br J Cancer; 2012 Jan; 106(3):508-16. PubMed ID: 22187035
[TBL] [Abstract][Full Text] [Related]
7. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
9. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
[TBL] [Abstract][Full Text] [Related]
10. Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer.
Brungs D; Lynch D; Luk AW; Minaei E; Ranson M; Aghmesheh M; Vine KL; Carolan M; Jaber M; de Souza P; Becker TM
World J Gastroenterol; 2018 Feb; 24(7):810-818. PubMed ID: 29467551
[TBL] [Abstract][Full Text] [Related]
11. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
12. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.
Khoja L; Lorigan P; Zhou C; Lancashire M; Booth J; Cummings J; Califano R; Clack G; Hughes A; Dive C
J Invest Dermatol; 2013 Jun; 133(6):1582-90. PubMed ID: 23223143
[TBL] [Abstract][Full Text] [Related]
13. A pilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancers.
Sclafani F; Smyth E; Cunningham D; Chau I; Turner A; Watkins D
Clin Colorectal Cancer; 2014 Jun; 13(2):94-9. PubMed ID: 24332356
[TBL] [Abstract][Full Text] [Related]
14. The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy.
Lowes LE; Lock M; Rodrigues G; D'Souza D; Bauman G; Ahmad B; Venkatesan V; Allan AL; Sexton T
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):358-64. PubMed ID: 26238233
[TBL] [Abstract][Full Text] [Related]
15. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
Zhou J; Dong F; Cui F; Xu R; Tang X
Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S
Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697
[TBL] [Abstract][Full Text] [Related]
17. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
[TBL] [Abstract][Full Text] [Related]
18. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
[TBL] [Abstract][Full Text] [Related]
20. Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.
Paoletti C; Li Y; Muñiz MC; Kidwell KM; Aung K; Thomas DG; Brown ME; Abramson VG; Irvin WJ; Lin NU; Liu MC; Nanda R; Nangia JR; Storniolo AM; Traina TA; Vaklavas C; Van Poznak CH; Wolff AC; Forero-Torres A; Hayes DF;
Clin Cancer Res; 2015 Jun; 21(12):2771-9. PubMed ID: 25779948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
